Table 3.
Cumulative confounder-adjusted VE estimates (adjusted for symptom onset, sex, age and chronic conditions) by time since last dose and SARS-CoV-2 variant in SARI patients who had received two doses of AZD1222 and were hospitalised between June 1st, 2021, and September 5th, 2022.
| Time since last dose of AZD1222 | VE by SARS CoV-2 variant, % (95% CI) |
||||
|---|---|---|---|---|---|
| Alpha | Beta | Delta | Omicron | Missing | |
| Time period | |||||
| 2 to ≤8 weeks | NE | NE | 92.9 (−15.8 to 99.6) | NE | 97.4 (62.0–99.8) |
| >8 to ≤16 weeks | NE | NE | 78.8 (−1.2 to 95.6) | NE | 84.3 (46.5–95.4) |
| >16 to ≤24 weeks | NE | NE | 58.4 (−26.8 to 86.4) | 74.8 (−584.7 to 99.1) | 66.6 (24.0–85.4) |
| >24 to ≤32 weeks | NE | NE | 87.9 (−73.3 to 99.2) | −26.9 (−622.3 to 77.7) | 86.7 (6.7–98.1) |
| >32 weeks | NE | NE | NE | 46.9 (−693.3 to 96.5) | 76.8 (−132.1 to 97.7) |
| Cumulative time | |||||
| ≤8 weeks | NE | NE | 92.9 (−15.8 to 99.6) | NE | 97.4 (62.0–99.8) |
| ≤16 weeks | NE | NE | 85.0 (41.3–96.2) | NE | 89.1 (65.6–96.6) |
| ≤24 weeks | NE | NE | 71.0 (30.7–87.9) | 74.8 (−584.9 to 99.1) | 76.6 (53.3–88.3) |
| ≤32 weeks | NE | NE | 71.8 (34.0–87.9) | −9.5 (−462.6 to 78.7) | 77.5 (55.9–88.5) |
| All | NE | NE | 72.0 (34.7–88.0) | 11.0 (−250.3 to 77.4) | 78.1 (58.2–88.6) |
CI = confidence interval. VE = vaccine effectiveness. NE = not estimable. SARI = severe acute respiratory infection. SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.